Valeant quarterly revenue totals $1.54 billion

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Valeant Pharmaceuticals reported $1.54 billion in total revenue for the third quarter, a 74% increase from the same period in 2012, according to a press release.

Product sales totaled $1.5 billion, up from $852.7 million in the same period in 2012.

Developed markets revenue totaled $1.14 billion, a 77% increase from the third quarter 2012, mainly attributed to the acquisition of Bausch + Lomb.

Emerging markets revenue totaled $399 million, a 68% increase from the same period in 2012, also resulting primarily from the acquisition of Bausch + Lomb.

Valeant reported a net loss of $973 million for the third quarter, a loss of $2.92 per share, because of one-time impairment charges, settlement of a contract dispute, and restructuring, integration and other charges mostly stemming from the acquisition of Bausch + Lomb.

Research and development costs totaled $49 million, up from $19 million in the third quarter 2012.

For the 9-month period ending Sept. 30, revenue totaled $3.7 billion, up from $2.6 billion in the same period of 2012. Product sales totaled $3.6 billion, up from $2.3 billion a year earlier.